7.2 Analgesics, NSAIDs, Opioids & Conscious Sedation Pharmacology

7.2 Analgesics, NSAIDs, Opioids & Conscious Sedation Pharmacology

Effective pain management and anxiety control are essential pillars of clinical dentistry. UK dental practitioners must master the pharmacodynamics, pharmacokinetics, adverse effect profiles, and contraindications of analgesics and sedatives prescribed under the Dental Practitioners' Formulary (DPF) and SDCEP guidelines.

Pathophysiology of Inflammatory Dental Pain

Odontogenic pain primarily arises from acute inflammatory responses within the dental pulp or periodontal tissues. Mechanical, thermal, or bacterial injury triggers the arachidonic acid cascade:

1. Phospholipase $A_2$ Activation: Membrane phospholipids are converted into arachidonic acid.
2. Cyclooxygenase Pathway: Cyclooxygenase enzymes ($COX-1$ and $COX-2$) convert arachidonic acid into unstable endoperoxides, which are subsequently synthesized into prostaglandins ($PGE_2$, $PGI_2$), thromboxane $A_2$ ($TXA_2$), and prostacyclin.
3. Peripheral Sensitization: Prostaglandin $PGE_2$ directly sensitizes peripheral A-$\delta$ and C nociceptors to inflammatory mediators such as bradykinin, histamine, and 5-hydroxytryptamine (serotonin), lowering the activation threshold for pain impulses.

$$\text{Membrane Phospholipids} \xrightarrow{\text{Phospholipase } A_2} \text{Arachidonic Acid} \xrightarrow{\text{COX-1 / COX-2}} \text{Prostaglandins (PGE}_2, \text{PGI}_2\text{)}$$

---

Non-Opioid Analgesics: Paracetamol & NSAIDs

Paracetamol (Acetaminophen)

• Mechanism of Action: Paracetamol acts predominantly within the CNS. It inhibits central cyclooxygenase enzymes (often designated $COX-3$ or peroxidase peroxidase site inhibition) and modulates descending serotonergic inhibitory pain pathways. It possesses potent analgesic and antipyretic activity but minimal peripheral anti-inflammatory action.
• Standard Dosing: Adult dose is 1 g (two 500 mg tablets) 4–6 hourly, up to a maximum of 4 g per 24 hours. Pediatric dosing is 15 mg/kg per dose.
• Hepatotoxicity & Metabolism in Overdose:
  • At therapeutic doses, 90% of paracetamol undergoes hepatic conjugation via glucuronidation and sulfation into nontoxic metabolites. Approximately 5–10% is metabolized by cytochrome P450 (CYP2E1) into a highly reactive, toxic electrophilic intermediate: $N$-acetyl-$p$-benzoquinone imine (NAPQI).
  • Under normal conditions, NAPQI is rapidly detoxified by conjugation with hepatic glutathione and excreted renally.
  • In acute overdose ($\ge 75–150$ mg/kg or $> 8–10$ g total), glucuronidation/sulfation pathways become saturated. Hepatic glutathione stores are rapidly depleted by $> 70\%$. Unbound NAPQI covalently binds to cysteine residues on hepatocyte proteins, inducing acute hepatocellular necrosis and fulminant hepatic failure.
• Antidotal Treatment: Emergency hospital admission. Treatment is guided by plasma paracetamol concentrations plotted on the Rumack-Matthew nomogram. Intravenous $N$-acetylcysteine (NAC) acts as a precursor for glutathione synthesis and directly inactivates NAPQI. NAC is most effective when administered within 8 hours of overdose.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

• Mechanism of Action: NSAIDs competitively inhibit $COX-1$ (constitutively expressed in stomach, kidneys, and platelets) and $COX-2$ (inducible at sites of tissue inflammation). By blocking prostaglandin $PGE_2$ synthesis, NSAIDs suppress peripheral nociceptor sensitization.
• Common Dental NSAIDs: Ibuprofen (400 mg TDS/QDS, max 2.4 g/day) and Naproxen (250–500 mg BD).
• Multimodal Analgesic Efficacy: Clinical trials demonstrate that combining Ibuprofen 400 mg with Paracetamol 1000 mg provides superior analgesia for postoperative dental pain with a lower Number Needed to Treat (NNT ~1.5) than weak opioid combinations (e.g., codeine 60 mg + paracetamol 1000 mg, NNT ~2.2).
• Clinical Contraindications & Adverse Effects:
  • Gastrointestinal Toxicity: Inhibition of $COX-1$-derived $PGE_2$ and $PGI_2$ impairs gastric mucosal blood flow, bicarbonate secretion, and mucus barrier formation, causing peptic ulceration and GI hemorrhage. Patients at high risk require co-prescription of a Proton Pump Inhibitor (e.g., Omeprazole 20 mg OD).
  • Renal Impairment: Prostaglandins maintain renal afferent arteriolar vasodilation. NSAIDs cause renal vasoconstriction, sodium retention, and acute kidney injury (AKI). Contraindicated in severe renal impairment (eGFR $< 30$ mL/min).
  • Asthma Exacerbation: Aspirin-Exacerbated Respiratory Disease (AERD / Samter's Triad). Blocking COX shunts arachidonic acid into the 5-lipoxygenase (5-LOX) pathway, causing overproduction of cysteinyl leukotrienes and severe bronchospasm in ~10-15% of asthmatic patients.
  • Cardiovascular Risk: High-dose NSAIDs and selective $COX-2$ inhibitors disrupt the balance between endothelial prostacyclin ($PGI_2$, anti-thrombotic) and platelet thromboxane ($TXA_2$, pro-thrombotic), increasing the risk of myocardial infarction and ischemic stroke. Contraindicated in severe heart failure (NYHA III/IV) and established ischemic heart disease.
  • Third Trimester of Pregnancy: Causes premature closure of the fetal ductus arteriosus and delays labor onset.

---

Opioid Analgesics in Dental Practice

Opioids are second-line analgesics indicated only when non-opioid combinations fail or are contraindicated.

Mechanism of Action

Opioids act as agonists at G-protein-coupled $\mu$ ($\mu$-opioid), $\kappa$ (kappa), and $\delta$ (delta) receptors in the brain, spinal cord, and peripheral nervous system. $\mu$-receptor activation inhibits adenylate cyclase, decreases intracellular cAMP, closes presynaptic voltage-gated $Ca^{2+}$ channels (reducing neurotransmitter release like Substance P), and opens postsynaptic $K^+$ channels (hyperpolarizing nociceptive neurons).

Codeine Phosphate

• Prodrug Pharmacology: Codeine has weak intrinsic affinity for $\mu$-receptors. It relies on metabolic conversion in the liver by cytochrome P450 2D6 (CYP2D6) into active morphine.
• Genetic Polymorphism:
  • Poor Metabolizers (~7–10% of Caucasians): Lack functional CYP2D6 enzymes and gain negligible analgesic relief from codeine.
  • Ultra-Rapid Metabolizers (~3–5% of populations): Possess gene duplications resulting in rapid conversion to morphine, predisposing them to life-threatening opioid toxicity even at standard doses.
• MHRA Safety Restrictions: Codeine is strictly contraindicated in children under 12 years of age, pediatric patients undergoing tonsillectomy/adenoidectomy, and breastfeeding mothers.

Dihydrocodeine & Tramadol

• Dihydrocodeine: 30 mg 4–6 hourly (max 240 mg/day). Similar efficacy to codeine with significant risk of constipation, nausea, and drowsiness.
• Tramadol: Dual mechanism: weak $\mu$-opioid agonist plus neuronal serotonin and norepinephrine reuptake inhibition (SNRI). Carries a risk of serotonin syndrome and lowers the seizure threshold.

Opioid Adverse Effects & Overdose Reversal

• Side Effects: Nausea, vomiting (stimulation of the chemoreceptor trigger zone), constipation (inhibition of gut motility), sedation, euphoria, urinary retention, and respiratory depression (blunting brainstem respiratory center sensitivity to $CO_2$).
• Opioid Antagonist: Intravenous or intramuscular Naloxone (0.4–2 mg) rapidly reverses opioid-induced respiratory depression by competitive receptor antagonism.

---

Conscious Sedation Pharmacology in UK Dental Practice

Conscious sedation in dentistry is governed by the Intercollegiate Advisory Committee for Sedation in Dentistry (IACSD) guidelines. Conscious sedation is defined as a technique in which the use of a drug or drugs produces a state of depression of the central nervous system enabling treatment to be carried out, but during which verbal contact with the patient is maintained throughout.

Inhalation Sedation (Nitrous Oxide / Oxygen)

• Pharmacodynamics: Nitrous oxide ($N_2O$) acts as a non-competitive NMDA receptor antagonist in the CNS, enhances $GABA_A$ receptor activity, and triggers endogenous opioid peptide release in the periaqueductal gray area.
• Pharmacokinetics: Characterized by an extremely low blood-gas partition coefficient (0.47). $N_2O$ is poorly soluble in blood, resulting in rapid induction and rapid elimination (recovery within minutes).
• Administration: Delivered using a dedicated relative analgesia (RA) machine equipped with anti-hypoxia safety features (minimum 30% $O_2$ flow). Titrated incrementally up to a typical maintenance dose of 30–50% $N_2O$.
• Diffusion Hypoxia (Fink Effect): Upon termination of inhalation sedation, $N_2O$ diffuses out of the pulmonary capillary blood into the alveoli down a steep concentration gradient in massive volumes. This high-volume influx dilutes alveolar oxygen and carbon dioxide, leading to transient arterial hypoxia. Prevention: Administer 100% Oxygen for 3–5 minutes immediately upon ending $N_2O$ delivery.
• Occupational Hazard & Chronic Toxicity: Chronic occupational exposure to scavenging-deficient $N_2O$ oxidizes the cobalt atom of Vitamin $B_{12}$, irreversibly inactivating methionine synthase. This impairs DNA synthesis and myelin formation, causing megaloblastic anemia and subacute combined degeneration of the spinal cord.

Intravenous Sedation (Midazolam)

• Pharmacological Profile: Midazolam is a short-acting imidazobenzodiazepine. It is water-soluble in acidic ampoules (pH 3.5), but at physiological pH (7.4), the diazepine ring closes, rendering the molecule highly lipophilic. It rapidly crosses the blood-brain barrier with an onset of action of 2–3 minutes.
• Mechanism of Action: Binds to the specific benzodiazepine site on the $\alpha$ subunit of the $GABA_A$ receptor complex. It acts as a positive allosteric modulator, increasing the frequency of chloride ($Cl^-$) channel opening upon GABA binding. Chloride influx hyperpolarizes the neuronal membrane, enhancing CNS inhibition.

$$\text{Midazolam} + \text{GABA}_A \text{ Receptor} \longrightarrow \uparrow \text{Cl}^- \text{ Channel Opening Frequency} \longrightarrow \text{Hyperpolarization}$$

• Clinical Titration Protocol: Administer through an indwelling IV cannula in a peripheral vein of the hand or arm. Titrate slowly to the individual patient's response while maintaining verbal contact and monitoring breathing and circulation; do not use a fixed dose or rapid bolus. Keep IV access until the patient is fit for discharge. Elimination half-life ($t_{1/2}$) is 1.5–2.5 hours.
• Benzodiazepine Antagonist — Flumazenil:
  • Mechanism: Competitive antagonist at the benzodiazepine site on the $GABA_A$ receptor.
  • Adult reversal after procedural sedation: Give 200 $\mu$g IV over 15 seconds. If consciousness has not adequately improved within 60 seconds, give 100 $\mu$g, repeating at 60-second intervals if needed, to a total maximum of 1 mg. This is the adult anaesthesia/procedural-sedation regimen, not the intensive-care overdose regimen. Flumazenil SmPC, section 4.2.
  • CRITICAL WARNING — Re-sedation Risk: Flumazenil has a short elimination half-life (~60 minutes), whereas midazolam's half-life is 1.5–2.5 hours. As flumazenil clears from plasma, midazolam re-occupies $GABA_A$ receptors, precipitating re-sedation and recurrent respiratory depression. Continue observation for recurrent sedation and respiratory depression for a period appropriate to the benzodiazepine dose, duration of effect, and patient factors; hepatic impairment may require longer observation. Reversal does not replace airway and ventilatory support or establish readiness for discharge.

---

Comparison of Dental Analgesics & Sedatives